menu
    • menu
    [{"orgOrder":0,"company":"Pharmapark","sponsor":"Pharmapark","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Partners with Pharmapark to Market BAT2506 in Russia and other CIS Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pharmapark","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmapark \/ Pharmapark","highestDevelopmentStatusID":"6","companyTruncated":"Pharmapark \/ Pharmapark"},{"orgOrder":0,"company":"Pharmapark","sponsor":"Prestige BioPharma Pte Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Bevacizumab Biosimilar in Russia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmapark","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmapark \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Pharmapark \/ Pharmapark"},{"orgOrder":0,"company":"Pharmapark","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT2206, a Stelara\u00ae Biosimil","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Pharmapark","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pharmapark \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Pharmapark \/ Pharmapark"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmapark

    Menu

    Pharmapark

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmapark

                            Russia arrow
                            Discovery on Target
                            Not Confirmed

                            Pharmapark

                            Russia arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Bio-Thera Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT...

                            Details : This partnership will leverage Pharmapark’s strong local presence, sales and marketing capabilities in Russia and other CIS countries. Bio-Thera will be responsible for full development, and commercial supply of BAT2206 out of its manufacturing facilit...

                            Brand Name : BAT2206

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 16, 2021

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Bio-Thera Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmapark

                            Russia arrow
                            Discovery on Target
                            Not Confirmed

                            Pharmapark

                            Russia arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Prestige BioPharma Pte Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Bevacizuma...

                            Details : The partnership arrangement includes the exclusive rights for Pharmapark to commercialize the Bevacizumab biosimilar in the Russian Federation, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing new...

                            Brand Name : HD204

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 15, 2021

                            Lead Product(s) : Bevacizumab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Prestige BioPharma Pte Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmapark

                            Russia arrow
                            Discovery on Target
                            Not Confirmed

                            Pharmapark

                            Russia arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Pharmapark

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bio-Thera Solutions Partners with Pharmapark to Market BAT2506 in Russia and other CIS Countries

                            Details : Bio-Thera has reached a licensing agreement with Pharmapark LLC, for BAT2506, its golimumab biosimilar, under which Pharmapark will have exclusive rights to distribute and market the drug with a status of a local product in Russia and other CIS countries...

                            Brand Name : BAT2506

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 17, 2020

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Pharmapark

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth